Table 3 Top 20 in the number of adverse events reports of Lanreotide and octreotide.
Lanreotide | n | Octreotide | n |
|---|---|---|---|
Diarrhoea | 1457 | blood pressure increased | 1834 |
Injection site pain | 595 | malignant neoplasm progression | 1735 |
Abdominal pain | 549 | abdominal pain | 1526 |
Injection site mass | 362 | blood pressure systolic increased | 1483 |
Flatulence | 262 | inappropriate schedule of product administration | 1367 |
Abdominal distension | 234 | body temperature decreased | 859 |
Disease progression | 224 | heart rate decreased | 660 |
Cholelithiasis | 198 | injection site mass | 620 |
Neoplasm progression | 198 | metastases to liver | 591 |
Flushing | 176 | blood pressure diastolic decreased | 541 |
Injection site nodule | 118 | blood pressure decreased | 508 |
Insulin-like growth factor increased | 100 | stress | 477 |
Blood glucose decreased | 100 | flatulence | 472 |
Hypoglycaemia | 98 | cholelithiasis | 462 |
Heart rate decreased | 98 | intestinal obstruction | 380 |
Intestinal obstruction | 87 | second primary malignancy | 378 |
Hepatic neoplasm | 62 | neoplasm progression | 344 |
Metastases to liver | 58 | neuroendocrine tumour | 324 |
Glycosylated haemoglobin increased | 58 | neoplasm | 277 |
Faeces discoloured | 57 | terminal state | 219 |
